Overview of VALNEVA's Shares and Voting Rights
VALNEVA, a prominent player in the biotech industry, has recently issued an important declaration concerning its shares and voting rights as of a specific date in the latter part of 2025. This announcement is crucial for stakeholders looking to stay informed about developments within the company.
Company Information
The organization, VALNEVA, maintains its registered office in Saint-Herblain, France, and operates within a regulated market on the Euronext Paris exchange. This background underscores its established presence within the financial markets, contributing to its credibility and established track record in biotechnology.
Key Declared Figures
According to the recent declaration, VALNEVA's share capital is composed of approximately 171,958,275 ordinary shares. Each share carries a par value of €0.15. This extensive shareholding highlights the company’s robust structure, essential for maintaining investor confidence and facilitating future growth.
Voting Rights Details
A significant aspect of this declaration is the total number of voting rights associated with these shares. It stands at 187,846,678, which includes suspended voting rights. This figure is crucial for understanding the control and influence shareholders possess over corporate decisions.
Recent Changes in Share Structure
Among the noteworthy changes listed, there was a transfer into bearer form of 235,387 shares entitling investors to double voting rights. Additionally, there was a definitive attribution of 103,419 free ordinary shares. These changes reflect proactive adjustments that may enhance shareholder value and engagement.
Clarifications on Voting Rights
It is essential to clarify that the theoretical voting rights mentioned are used as the basis for calculating threshold crossings in accordance with regulatory requirements. This measure ensures transparency in how voting rights are calculated and reported.
Legal Compliance and Reporting
According to Article 223-11 of the AMF General Regulations, the total voting rights number encompasses all shares with voting rights, including those with temporarily suspended rights. As such, investors are encouraged to understand the implications of these figures when contemplating their involvement with VALNEVA.
Conclusion and Future Outlook
As VALNEVA continues to evolve within the biotech landscape, it remains pivotal for investors and potential stakeholders to remain engaged with updates regarding its share structure and voting rights. The overall health of the company and its commitment to transparent reporting is indicative of its vision for sustained innovation and growth in the sector.
Frequently Asked Questions
What is VALNEVA's current share capital?
VALNEVA's share capital comprises approximately 171,958,275 ordinary shares.
How many voting rights does VALNEVA have?
There are a total of 187,846,678 voting rights, including those that are currently suspended.
What changes were recently made to VALNEVA's shares?
Recent changes included the transfer of bearer shares with double voting rights and the assignment of free ordinary shares.
Why are theoretical voting rights important?
Theoretical voting rights are significant as they serve as a basis for understanding voting thresholds and shareholder influence in corporate matters.
How does VALNEVA ensure compliance with regulations?
VALNEVA adheres to Article 223-11 of the AMF General Regulations to ensure accurate reporting of all shares with voting rights.
